Approved
consistent with NIH documents and memos submitted to OMB. With
respect to the prior terms of clearance: 1 and 2) OMB had reviewed
NIEHS' responses to items 1 and 2 (re: study oversight) in 2003.
Documentation was provided. 3) There was likely a miscommunication
regarding the Vanguard phase; perhaps the terms of clearance were
actually written before the agreement was reached. Regardless,
however, the "term" was meant to cover substantive changes in
content. Since NIEHS did not make any such changes (as per the
response provided), there is nothing additional that they needed to
do here (other than document that no changes in content were made).
4) The concept behind this term was really to assure that all
relevant agencies were involved so that consistent decisions could
be made about investments in laboratory methods, capacity, and
storage for biomarkers as well as ensuring broad knowledge of this
resource across agencies to so that other agencies could capitalize
on both the methods generated and the data available, thereby
avoiding duplication of effort. Appropriate agencies seem to be on
the advisory board. Publication of articles regarding the study
design and recruitment are in the works which will further
disseminate information. 5) In general, the oversight plan looks
fine. OMB suggested that the "Sister Study Collaborative
Application" be modified to include questions regarding the
availability of data for the confounders and effect modifiers
appropriate for the hypothesis being tested (this is slightly
different from the questions being asked in E10). 6) The
recruitment, enrollment, and (limited) follow up rates for the
Sister Study thus far are impressive.
Inventory as of this Action
Requested
Previously Approved
09/30/2009
36 Months From Approved
09/30/2006
82,340
0
67,527
64,710
0
63,438
0
0
0
This is an investigation of the
independent and joint effects of genetic susceptibility and
environmental, biological, and lifestyle factors on the risk of
breast cancer. A cohort of 50,000 women ages 35-74 who are the
cancer free sisters of women who have had breast cancer will be
followed for 10 or more years. Baseline questionnaire data, fasting
blood, first morning urine, dust and toenail samples will be
obtained.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.